Bill Anderson/LinkedIn
Nov 26, 2025, 11:37
Bill Anderson on Secondary Stroke Prevention: This Week, We’ve Reached a Significant Milestone
Bill Anderson, CEO at Bayer, shared on LinkedIn:
”Those numbers tell the story: stroke is devastating.
For patients. For families.
And after surviving, the risk of another stroke is even higher.
This week, we’ve reached a significant milestone with positive topline results from our international Phase III study in secondary stroke prevention.
Our teams worked hard to get here.
Thank you, Team Bayer, for pushing to help people who’ve already been through so much.
We’re making progress—and there’s more to do.”

Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
